Introduction
Prior to 2010, allogeneic hematopoietic cell transplant (alloHCT) was the only curative treatment for patients with high-grade lymphoma relapsed after autologous HCT (autoHCT), relapsed acute lymphoblastic leukemia (ALL), and advanced chronic lymphocytic leukemia (CLL). Dramatic reports of the success of chimeric antigen receptor (CAR) T cell therapy in treating patients with relapsed or refractory disease [1, 2] and the duration of some remissions have raised the possibility that some responding patients may be cured. Six studies presented in the past 2 years, the Phase II expansion cohort of ZUMA-1 These data contributed to the recent FDA approvals for CAR-T cell therapy in the treatment of children and young adults with relapsed/refractory ALL and adults with relapsed/ refractory DLBCL. In addition to the FDA-approved indications, the availability of clinical trials led to the consideration of CAR-T cell therapy in patients with B cell malignancies that are either multiply relapsed, refractory to chemo-or immunotherapy, or that have relapsed following alloHCT. The data also create clinical scenarios where both CAR-T therapy and alloHCT could be considered. CAR-T therapy is an attractive option to reduce or eliminate residual disease prior to alloHCT, because CAR-T therapy has low treatment-related mortality, and because studies of patients with low-or highgrade follicular lymphoma (FL) [9] , ALL [10-12], Hodgkin's disease (HD) [13] or DLBCL [14] have consistently shown that transplants performed in the presence of active disease have inferior outcomes and higher rates of relapse.
In this review, we begin by addressing whether prior therapies, including alloHCT, impact the safety or efficacy of CAR-T cell therapy. Next, for specific hematologic diseases, This article is part of the Topical Collection on CART and Immunotherapy we review evidence that guide two critical decisions: first, whether to offer CAR-T therapy to patients with residual disease or to proceed directly with alloHCT, and second, given the knowledge that pre-transplant preparative regimens will likely wipe out CAR-T cells, whether to consolidate remissions obtained via CAR-T cell therapy though the use of alloHCT or to delay transplantation until there is evidence of progressive disease. Finally, we review some general factors to consider with regard to initiating transplant or CAR-T cell therapies in patients who are potential transplant candidates.
Impact of Prior Therapy on CAR-T Cell Therapy Safety and Efficacy
The use of CAR-T cell therapy requires in vitro expansion of lymphocytes transduced with a gene encoding the CAR protein and infusion of the cell product into patients [15, 16, 17•] . Among patients previously treated with alloHCT, these lymphocytes are derived from the donated stem cell graft. Donor lymphocyte infusion is an effective practice for patients who relapse after alloHCT and have low donor chimerim, but is followed by the development of graft versus host disease (GVHD) in approximately 45% of treated patients [11] . Infusion of allogeneic lymphocytes modified with a CAR could also result in GVHD. Surprisingly, in three separate studies of patients with ALL [8••, 18, 19] and an additional study of patients with CLL and B cell lymphoma [20] who had relapsed following alloHCT, none developed GVHD when subsequently treated with CAR-T cells despite the allogeneic origin of the cells. The reason for this difference is not understood. Nonetheless, clinical experience shows that the major toxicities of CAR-T cell therapy, including the cytokine release syndrome and neurotoxicity, are not apparently increased by prior allogeneic transplantation [19, 21] .
Review of recent key clinical trials of CAR-T cells (summarized in Table 1 ) support the hypothesis that there is little, if any, influence of the number of prior lines of chemotherapy or prior use of the bi-specific T cell engager (BiTE), blinatumomab [29] , on the success of CAR-T cell therapy. Two potential mechanisms may result in therapeutic resistance: patients may develop immunity to the protein sequence within the CAR binding domain and reject cells expressing CAR protein [19, 33] or the shared epitopes may exert strong selective pressure favoring the emergence of antigen-negative tumor variants [34••] . In the case of ALL, initial findings reported complete remissions (CRs) following treatment with CAR-T cells in two of three patients that had experienced relapses after blinatumomab [18] , suggesting that relapse following this CD19-directed antibody therapy does not preclude success of CD19-directed CAR-T cell therapy (though in one of the two patients, the remission lasted only 2 months). These data suggest that neither the number of failed prior lines of chemotherapy nor prior treatment with alloHCT have strong impacts on the outcome of patients treated with CAR-T cell therapy.
Specific Disease Considerations

Acute Lymphoblastic Leukemia
A complete remission is achieved in approximately 90% of adults with ALL following initial induction chemotherapy [35] . European and American expert panels recommend that allogeneic transplantation for adults with ALL be restricted to those in first remission with high-risk disease, those that fail to achieve a first remission, or those that suffer a subsequent relapse [36, 37] . The definition of high-risk adult ALL continues to evolve, but generally includes patients who present with a high white blood cell count, who harbor the Philadelphia chromosome (Ph + disease) or with Ph-like ALL [38] . Patients harboring mutations or translocation involving the mixed lineage leukemia (MLL) gene, including the t (4;11), may also be a high-risk group [39] . The persistence of minimal residual disease (MRD), defined as leukemia cells present below the frequency detectable by morphology [40] , at the time of allografting, predicts inferior transplant outcomes: in one study, patients who underwent alloHCT in the absence of MRD had a 3-year overall survival of 68% compared to only 40% for those transplanted at a time when MRD was detectable [11] . Thus, if HCT is being considered for patients with high-risk ALL in CR1, methods to obtain an MRD-negative CR may improve outcomes [41] .
If the decision is made to withhold HCT until after an initial relapse, a challenge then is to get patients back into second remission, since HCT outcomes are superior for patients in CR2 compared to those with refractory relapse. Studies of conventional chemotherapeutic approaches to adult patients with relapsed or recurrent ALL showed CR rates of 20 to 44% [42•, 43 •] and median overall survival of 24 weeks [44] . However, several newer therapies, including blinatumomab and inotuzumab ozogamacin [45] , have recently completed phase III trials showing impressive rates of response in relapsed or refractory ALL. In a phase three trial of 326 patients randomized 2:1 to either inotuzumab ozogamacin or standard chemotherapy, the CR rate was 80.7% with inotuzumab ozogamacin versus 29.4% with standard chemotherapy [28] . In addition, 78.4% of patients with a complete remission were found to be MRD negative [28] and 41% of patients proceeded to HCT. A similarly designed trial found that blinatumomab resulted in a CR or CR with incomplete count recovery in 44% of patients of whom 76% were MRD negative [29] . Despite these results, the median overall survival of patients treated with blinatumomab was 7.7 months, reinforcing the need for subsequent therapy. Venetoclax [31] AlloHSCT [32] CR 8%, PR 52% 10-year OS 51%
CD19-directed CAR-T cells offer another, perhaps more effective approach for patients with relapsed/recurrent or refractory ALL. A phase I/II trial from MSKCC enrolled 53 adults with ALL [8••] obtained CR in 83%, including 67% that were free of MRD. Among 9 patients in whom residual disease remained detectable, all relapsed; while among 32 patients without MRD, 16 patients relapsed. In this cohort, 26 patients achieved a complete remission following CAR-T cell infusion and were followed without further treatment. Nine of these patients remain alive at a median of 29 months of follow-up. Among 17 patients who proceeded to HCT, 5 remain alive, 6 relapsed, and 6 died from transplant-related toxicities. Comparing outcomes of the 32 patients that achieved an MRD-negative CR following CAR-T cell infusion, no difference in overall survival was seen between patients who completed HCT and those that did not.
A phase I trial at the University of Pennsylvania treated 30 young adults and children with relapsed/refractory ALL with CAR-T cells and found a CR rate of 90% and a 6-month eventfree survival rate of 67% [7] . As noted above, half of these patients had previously completed an alloHCT. Among 30 patients treated with a defined composition of CD4 + and CD8
, all patients achieved a complete remission when evaluated by bone marrow morphology, and 29 had no evidence of disease by high-resolution flow cytometry. At the time of publication, 12 of 17 patients (70%) treated with fludarabine plus cyclophosphamide lymphodepletion prior to CAR-T cell infusion remained alive and free of relapse, and 10 completed alloHCT. Overall, the rate of alloHCT following CAR-T cell therapy compares favorably to the 24% rate following treatment with blinatumomab [29] . CAR-T cell persistence is one key difference between trials that may impact clinical decision-making. The trial at MSKCC, which provides the longest follow-up of ALL patients treated with CAR-T cells, found no difference between event-free or overall survival between patients in whom the CAR-T cells persisted for more than or less than 14 days [8••]. However, cross-trial comparisons find shorter persistence of T cells (median 14 days) and higher rates of relapse or death among patients who achieved an MRD-negative CR (17 of 26, 58%) among patients reported by Park et al., as compared to patients who achieved an MRD-negative CR following treatment with tisagenlecleucel where the median duration of CAR-T persistence was 168 days and the risk of death or relapse by 1 year was only 41% [7•]. The reason for this difference is not known, but differences in the age of trial participants, manufacturing process, and CAR design, including the costimulatory domains used may be factors. Nevertheless, the observation that some of the patients reported by Park et al. achieved durable complete remissions in the absence of CAR-T cell persistence suggests that ongoing antileukemic activity of CAR-T cells may not be required for durable remissions [8••, 46] .
Taken together, the available data on CAR-T cells show that they are highly active in adults with recurrent or chemoresistant ALL, result in a complete remission in most patients, and that a subset of these remissions persist with no further therapy. Thus, there are likely to be several key roles of CAR-T cell therapy for ALL. One is to obtain remissions for patients in first relapse who are refractory or not eligible for other therapies in order to induce a remission prior to allogeneic transplantation. These patients may consider alloHCT as consolidation following successful remission with CAR-T cell therapy. A second possible role is to obtain an MRD-negative first remission in patients who have suboptimal responses to initial chemotherapy. An additional role is for treatment following relapse after alloHCT has failed. Among this population, a second myeloablative transplant is associated with increased toxicity and low success rates [47] , but newer preparative regimens may allow this approach to be feasible [48] . A central question is whether it will be possible to distinguish those CAR-T cell-induced CRs that will persist without further therapy from those that are likely to be short lived. If such a distinction was possible, the toxicities of alloHCT could be avoided in patients who may not require the additional therapy.
High-grade B Cell Lymphoma
Patients with DLBCL who relapse within 1 year after autoHCT or who are refractory to initial therapy have a dismal prognosis. This is well documented in the retrospective SCHOLAR-1 trial [23••] in which 861 refractory or relapsed patients had a 26% objective response and a 7% complete response to their next line of therapy. Use of newer agents (venetoclax or ibrutinib) does not significantly improve on this result [49, 50] . The combination of lenalidomide plus ibrutinib achieved an objective response rate of 44% and a complete response of 14% in a small group of patients [51] , but grade 3/4 adverse events occurred in 89% of patients treated and the duration of response has not been reported. Addition of ofatumumab to traditional salvage regimens such as DHAP resulted in a CR rate of 15%, and only 33% of patients completed a subsequent autoHCT [52] . These results provide a useful benchmark against which CAR-T cell therapy for DLBCL can be compared.
Given the dismal prognosis of non-transplant approaches to recurrent DLBCL, a number of investigators have explored the use of alloHCT following ablative or reduced intensity conditioning regimens [14, 27••, 53, 54] . Similar to ALL, transplants performed for DLBCL in the presence of active disease have inferior outcomes and higher rates of relapse. In the GITMO study of large cell lymphoma [14], pre-transplant disease status was the only variable to remain a significant predictor of outcomes in multivariate analysis (with 1-year overall survival being approximately 80%, 60%, and 50% for patients transplanted in complete remission, partial remission, and with chemorefractory disease respectively). Thus, patients most likely to benefit from alloHCT are those with few, if any, comorbidities, and with disease that is in either partial or complete remission.
Three All three trials showed impressive results in this difficult to treat population with manageable toxicity. The JULIET trial is notable for lower CR rates and longer time to infusion, but also allowed the use of bridging chemotherapy. The rate of CR reported from TRANSCEND was 58% among patients treated at dose level 2 (10 8 CAR-T cells), the highest of the three trials. Interestingly, no relationship between the number of prior lines of therapy and response was seen.
A key finding is that PR does not appear to be a meaningful endpoint in this setting: patients that failed to attain a complete response had a median progression-free survival of only 1.9 months after treatment with axicaptagene ciloleucel [3•] and 2.1 months after treatment with lisocabtagene maraleucel [26•]. In contrast, patients who remain alive and in complete remission 12 months after CAR-T cell therapy appear to be at very low risk of relapse. In the case of axicaptagene ciloleucel, the number of relapses after 12 months was zero [3•]. Taken together, these data suggest that CAR-T therapy is qualitatively distinct from chemotherapy: with the expectation that roughly 50% of the patients with DLBCL treated with CAR-T will experience a complete remission, and of these, approximately 60% will not show progression within the subsequent 12 months and might be cured. Of the 101 patients enrolled in ZUMA-1, only two subsequently completed alloHCT.
When would one consider alloHCT for DLBCL? Cross-trial comparisons show similar 1-year survival rates among patients with chemorefractory DLBCL treated with RIC alloHCT or CAR-T cell therapy; however, non-relapse mortality (NRM) of CAR-T cell therapy is approximately 3% while NRM associated with alloHCT is~30%. Thus, the above data provide a strong argument that CAR-T cell therapy supplants alloHCT for patients with chemorefractory DLBCL. In addition, low relapse rates after the first 12 months suggest that a substantial fraction of patients with DLBCL treated with CAR-T cells may be cured. Extrapolating from the GITMO study, one may hypothesize that outcomes could be optimized by targeting alloHCT to patients with responses that are unlikely to prove durable, i.e., patients treated with CAR-T cells who achieved no response or a partial response or patients that achieve a subsequent remission via conventional chemotherapy.
The impact of CAR-T therapy on the outcomes of subsequent transplant is unknown. Thus, to integrate the science of CAR-T cell therapy with transplantation, researchers must identify patients at high risk of relapse following CAR-T.
These high-risk patients may have a window of opportunity for good outcomes if offered a RIC alloHCT during CR. In an unselected population of patients treated with CAR-T cell therapy for DLBCL, the toxicity of a subsequent RIC alloHCT for patients in CR would likely outweigh any benefit.
Indolent Non-Hodgkin Lymphoma and CLL
Grades one and two follicular lymphoma (FL), mantel cell lymphoma (MCL), and small/chronic lymphocytic lymphoma (SLL/ CLL) represent indolent lymphomas that are frequently responsive to chemotherapy but are unlikely to be cured in the absence of transplantation. AlloHCT is an effective but infrequently used treatment strategy for FL, MCL, and CLL because other options have become available. For example, the 5-year survival after relapse of FL treated with salvage combination chemotherapy and autologous stem cell transplantation is nearly 70% [55] ; the expected 10-year overall survival is 66% [56] . Early progression is a poor prognostic factor correlated with historic 5-year overall survival measures near 50%, but recent improvements such as the incorporation of immunomodulatory medications, such as thalidomide and lenalidomide [57, 58] , and targeted agents [59] [60] [61] have improved the outlook of these patients. Mantle cell lymphoma represents a particularly challenging disease, but newer agents have shown some promise [62, 63] .
Recently, a registry analysis from CIBMTR of patients with FL found that RIC alloHCT resulted in a 5-year progressionfree survival of 58% and 5-year overall survival of 66% [27••], while patients who completed an autoHCT had a 5-year progression-free survival of 41%. In a landmark analysis of patients surviving >24 months, the authors report that beyond 2 years after transplant, the early toxicity of alloHCT becomes offset by lower relapse rates translates into an overall survival benefit of alloHCT. Similarly, long-term outcomes reported from the German CLL study group describe 10-year overall survival following alloHCT for high-risk or refractory CLL of 51% [32] .
CAR-T cell therapy is not yet approved by the FDA for treatment of indolent lymphomas. Because these tumors tend to be responsive to multiple therapies, short remissions alone provide limited value. Improved long-term outcomes, such as matching the 5-year survival of 66% seen from the CIBMTR, are a reasonable benchmark. Small trials of CAR-T cell therapy for CLL are encouraging; however, the results with low-grade lymphoma are mixed. Patients with ibrutinib refractory CLL treated with CAR-T cells at FHCRC had a CR rate of 71% at 4 weeks, with 58% having no malignant IGH sequences identified on deep sequencing. The absence of malignant IGH sequences was associated with progression-free survival of 100% at a median follow-up of 6.6 months [30] . Treatment of other indolent lymphomas with CAR-T cells was reported to result in a CR in 2 of 9 patients [6••]. Thus, CLL appears to be particularly responsive to CAR-T cells. Follicular lymphoma can follow either an indolent or an aggressive course. Among the 23 patients with follicular lymphoma treated with CTL019, the complete response rate was 71% and at a median follow-up of 28.6 months, 70% of patients remained progression free [24•]. Monitoring a subset of 16 patients with quantitative polymerase chain reaction for CAR-T cell persistence revealed that 8 had loss of CAR-T cells without an associated relapse. This finding, along with the plateau of the progression-free survival curve, suggests that, similar to the case with DLBCL and CLL, a subset of patients with aggressive follicular lymphoma may be cured by CAR-T cell therapy. Thus, while the option to engage in CAR-T cell therapy for indolent lymphomas and CLL is likely to be dictated by the availability of clinical trials, referral for such a therapy should be considered at the time of relapse following autoHCT or when progression following ibrutinib therapy is seen. This strategy would leave several targeted options (i.e., idelalisib, copanlisib [64] , and venetoclax [31, 65] ) in addition to salvage chemotherapy available for reinduction therapy enabling a possible subsequent alloHCT should the patient relapse after CAR-T cell therapy.
Multple Myeloma
Myeloma shares key features with CD19 + target malignancies: a target antigen, B cell maturation antigen (BCMA), has been identified that is highly expressed and mostly limited to the malignant cell population. As a result, "on target, off tumor" toxicity was expected to be limited, and indeed updated results from recent trials of the bb2121 CAR product showed no instances of dose-limiting toxicity or grade ≥ 3 neurotoxicity. BCMA targeted CAR-T cells showed modest success in early results of multiply refractory patients, with 2 of 6 patients achieving a CR or VGPR [66•] . Increasing the CAR-T cell dose to ≥ 150 × 10 6 cells significantly improved outcomes with ORR rates of 95% in 22 patients [67•, 68•] . Responses appear deep: 50% of patients obtained a CR, and 90% of these were negative for MRD. The rate of progression-free survival at 9 months was 71%. Importantly, the high cell dose remains associated with a tolerable safety profile. Consideration of BCMA CAR-T cell trials will depend on local availability and will likely be restricted to patients with relapsed/refractory disease. While the above results were limited to patients with high BCMA expression, future trials may expand eligibility, as even low levels of BCMA can trigger CAR-T cells in vitro [69•] . Follow-up data are limited; there is no data regarding transplant following treatment with BCMA CAR-T cells.
Acute Myeloid Leukemia
The challenges of myeloid leukemia set this disease target apart from B cell and plasma malignancies because no single clearly optimal target antigen has been defined. Very few antigens present on leukemic blasts are absent from normal maturing hematopoetic stem cells [70••] . As a result, CAR-T cells targeted at antigens present on HSCs cells may result in marrow aplasia. Though trials testing CAR-T cells targeting CD33, CD123, mesothelin, Muc1, CD56, CD38, or CD117 individually and in combination are in progress [71] , specific challenges exist in engineering CAR-T cells to respond to combinations of target antigens [72] . So-called logic gated CAR-T cells, which require the presence of two or more antigens, may overcome this limitation by gaining specificity. Early responses of myeloid leukemia to CD33 CAR-T cells have been brief, lasting~12 weeks [73] .
Transplant Following CAR-T Cell Therapy: the Importance of CAR-T Cell Persistence
A key feature of cellular immunotherapy is persistence of the transferred cells. In early studies of CAR-T cells for chronic lymphocytic leukemia, those with early cell proliferation and sustained CAR-T cell numbers achieved a complete remission [74] , whereas relapses occurred exclusively among patients with loss of the transfused cells. In patients with ALL, Maude et al. [7•] reported that following infusion, CAR-T cells were detectable for a median of 168 days, along with the expected associated B cell aplasia. Approximately 50% of relapsing patients developed loss of CD19 on their tumor. This supports the hypothesis that ongoing antitumor activity of CAR-T cells likely contributes to the maintenance of remissions in treated patients, and points to the general observation that two major routes of relapse are loss of CAR-T cells or loss of their target antigen on the tumor, i.e., CD19-negative relapse. While follow-up was brief, among 17 patients treated with fludarabine and cyclophosphamide conditioning, the only patient to relapse with CD19 + disease had completed an alloHCT. The duration of CAR-T cell persistence necessary for a long-term remission in the absence of subsequent alloHCT is unknown and may vary depending on disease type. These data also illustrate that alloHCT following CAR-T therapy risks effectively trades potentially persistent CAR-T cells that may be responsible for the ongoing maintenance of a remission for a non-specific graft-versus-leukemia effect.
Pace of Disease and Other Considerations
An important detail regarding interpretation of the results of trials of CD19-directed CAR-T therapy lies in the implicit selection criteria imposed by the manufacture of a modified cell therapy product. CAR-T cell therapy requires apheresis of the patient's blood, isolation of circulating Tcells, gene transfer, usually with a viral vector, and subsequent expansion in the cell-processing facility prior to infusion back into the patient [5••]. The manufacture times for these products are typically between 2 and 3 weeks. Lymphodepletion prior to modified CAR-T cell infusion is usually delayed until the modified cell product is cleared for clinical use. As a result, patients with rapidly progressing disease may not be able to wait to begin treatment. Reviewing the high rates of production success and infusion without the need for patients to withdraw from trials to receive urgent chemotherapy may suggest that these trials enrolled patients who were both medically fit and could wait several weeks to initiate therapy. This trial design may bias against patients with aggressive disease and improve apparent outcomes relative to a cohort enrolled at presentation (rather than at treatment).
In the future, "intent to treat" trial designs that allow bridging chemotherapy may reduce bias. In addition, improved technologies such as virus-free techniques that rely on DNA transposases are likely to speed manufacture [75, 76] and the use of geneediting techniques to disrupt the endogenous T cell receptor [77] or the use of engineered NK cells [78] may provide a "universal" product available "off the shelf" to patients regardless of matched histocompatability. These innovations will likely broaden the types of patients who benefit from CAR-T cell therapy.
Recent data suggest that outcomes following use of alternative donor stem cell sources, specifically haploidentical family members [79] and banked cord blood (CB) units [80] , are similar to those following transplant with matched unrelated donors. These results have made allogeneic stem cell grafts available for nearly all patients, and therefore donor availability seldom enters into the decision to initially pursue a CAR-T cell approach versus an allogeneic transplant. In the case of the DLBCL, matched related donors were compared to unrelated donors matched at 8 of 8 major histocompatibility loci and no impact of donor type (sibling donor versus matched unrelated) was found on overall survival [53] ; similar recent results for patients with ALL were also reported [81] . The Italian group found Hodgkin disease patients with an available allogeneic donor had improved survival in comparison to those patients for whom an allogeneic donor was not available [13] . However, this cohort did not list patients with available suitable CB units, and only 13% of the patients in the "donor available" group received a haploidentical HCT.
It is unlikely that patients' other pretreatment characteristics will identify alloHCT or CAR-T cell therapy as a preferred treatment. None of the recent CAR-T cell trials has shown an association between prior treatment (either prior autoHCT, prior alloHCT, or the number of prior chemotherapy regimens) and outcome. While patient selection for alloHCT has been increasingly refined through the use of predictive algorithms that can define the likelihood of non-relapse mortality within the first 2 years after transplant [82] , such algorithms do not yet exist for CAR-T cell therapy, making comparisons between predictive risk scores impossible. Baseline pretreatment factors identified by Sorror et al. [82] predict non-relapse mortality associated with both myeloablative and nonmyeloablative alloHCT. These factors can stratify patient groups with probabilities of 2-year overall survival as high as 71% or as low as 34%. However, patients identified as high risk for alloHCT may not have other attractive treatment options, so transplantation, though high risk, may still offer the best chance of both short and long-term survival. Indeed, criteria identifying patients as high risk for alloHCT (principally the presence of organ dysfunction) were also exclusion criteria for several pivotal trials of CAR-T cell therapy [3•, 4•, 6••, 22].
Differences in the characters of risk across the two treatment types may influence patient decision-making. Whereas the principle toxicity risk of CAR-T cell therapy is acute [83, 84] , the long-term morbidity associated with GVHD [85, 86] is a unique feature of alloHCT. Thus, it remains challenging to quantitatively compare the risks of alloHCT and CAR-T therapy for individual patients.
Conclusions
The rapid growth of new treatment options for diseases with historically dismal prognoses [23••, 62, 87] is both exciting and challenging. As these data are new, significant uncertainty remains. The choice to offer HSCT to patients following CAR-T cell therapy relies on historical experience that transplantation has been the only curative option for the subset of patients with relapsed aggressive B cell malignancies. As experience with CAR-T cell therapy grows and long-term remissions prove durable, the use of transplantation may be further refined.
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